Multicentric phase II trial of TI‐CE high‐dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors

Multicentric phase II trial of TI‐CE high‐dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors

ABSTRACT Background High‐dose chemotherapy (HDCT) with TI‐CE regimen is a valid option for the treatment of relapsed advanced germ cell tumors (GCT). We report a phase II trial with therapeutic drug monitoring of carboplatin for optimizing area under the curve (AUC) of this drug. Methods Patients wi...

Full description

Bibliographic Details
Main Authors:	Christine Chevreau, Christophe Massard, Aude Flechon, Rémy Delva, Gwenaëlle Gravis, Jean‐Pierre Lotz, Jacques‐Olivier Bay, Marine Gross‐Goupil, Karim Fizazi, Loïc Mourey, Angelo Paci, Jérôme Guitton, Fabienne Thomas, Bénédicte Lelièvre, Joseph Ciccolini, Sotheara Moeung, Yohan Gallois, Pascale Olivier, Stéphane Culine, Thomas Filleron, Etienne Chatelut
Format:	Article
Language:	English
Published:	Wiley 2021-04-01
Series:	Cancer Medicine
Subjects:	germ cell tumors high‐dose chemotherapy phase II trial relapsed patients therapeutic drug monitoring
Online Access:	https://doi.org/10.1002/cam4.3687

Similar Items

Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial
by: Stéphane Culine, et al.
Published: (2023-03-01)

Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
by: Luc Cabel, et al.
Published: (2017-04-01)

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer
by: Florent Puisset, et al.
Published: (2023-01-01)

How to improve adherence of guidelines for localized testicular cancer surveillance: A Delphi consensus study
by: Angélique Da Silva, et al.
Published: (2022-10-01)

Systemic treatment for metastatic prostate cancer
by: Gwenaelle Gravis
Published: (2019-04-01)

Randomized phase III trial of dose-dense MVAC or GC as perioperative chemotherapy for muscle-invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses
by: C. Pfister, et al.
Published: (2020-07-01)

Carboplatin-Induced Hypersensitivity Reaction
by: Evangelos Potolidis, et al.
Published: (2012-03-01)

Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
by: Sevgi Ayhan, et al.
Published: (2023-09-01)

COMPARISON BETWEEN GEMCITABINE-CARBOPLATIN AND COMBINATION OF GEMCITABINE-CARBOPLATIN AND CELECOXIB IN UROTHELIAL CARCINOMA CELL APOPTOSIS
by: Widya Sakti Pratama, et al.
Published: (2019-01-01)

Surgical treatments of superior semicircular canal dehiscence: A single‐centre experience in 63 cases
by: Pauline Nieto, et al.
Published: (2021-12-01)

Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
by: Félicien Le Louedec, et al.
Published: (2020-10-01)

Single-cell characterization of step-wise acquisition of carboplatin resistance in ovarian cancer
by: Alexander T. Wenzel, et al.
Published: (2022-06-01)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
by: Xiangbin Tan, et al.
Published: (2023-09-01)

Validity of Weekly Administration of Carboplatin after Carboplatin-Induced SIADH: Two Case Reports and Literature Review
by: Suguru Fujitsuka, et al.
Published: (2022-03-01)

The Affinity of Carboplatin to B-Vitamins and Nucleobases
by: Beata Szefler, et al.
Published: (2021-03-01)

Hypersensitivity and cross-reactivity to cisplatin and carboplatin
by: Gholamreza Faridaalaee, et al.
Published: (2016-07-01)

Subtenon Carboplatin in the Management of Intraocular Retinoblastoma
by: Reza Karkhaneh, et al.
Published: (2008-12-01)

Adaptation and validation of the memorial anxiety scale for prostate cancer (MAX-PC) in a sample of French men
by: Rajae Touzani, et al.
Published: (2019-09-01)

Endoplasmic reticulum stress is involved in the response of human laryngeal carcinoma cells to Carboplatin but is absent in Carboplatin-resistant cells.
by: Anamaria Brozovic, et al.
Published: (2013-01-01)

Comparison of Efficacy and Safety Between Liposome-paclitaxel plus Carboplatin and Paclitaxel plus Carboplatin on Epithelial Ovarian Cancer
by: HOU Wenjie, et al.
Published: (2018-06-01)

Carboplatin: molecular mechanisms of action associated with chemoresistance
by: Graziele Fonseca de Sousa, et al.
Published: (2014-12-01)

Experimental and Computational Investigations of Carboplatin Supramolecular Complexes
by: Sherif Ashraf Fahmy, et al.
Published: (2020-11-01)

Ischemic Colitis Associated with Paclitaxel and Carboplatin Combination
by: Ahmed Gamal Elsayed, et al.
Published: (2017-08-01)

Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients
by: Zhenhua Du, et al.
Published: (2015-07-01)

Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer.
by: Eric S Kim, et al.
Published: (2017-01-01)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
by: Yin Tao, et al.
Published: (2022-03-01)

Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology
by: Etienne Chatelut, et al.
Published: (2021-04-01)

Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems.
by: Bishnubrata Patra, et al.
Published: (2020-01-01)

A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study
by: Gwenaelle Gravis, et al.
Published: (2023-05-01)

Study of evaluation of Civil Servants' Performance (DP3)
by: , SATHYA, Moeung, et al.
Published: (2003)

Bilateral Optic Neuropathy Secondary to Intravenous Carboplatin Therapy
by: Arash Maleki, et al.
Published: (2024-03-01)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
by: Mohsen Ghaferi, et al.
Published: (2022-10-01)

The treatment of stage A testicular seminoma by carboplatin monochemotherapy
by: Bojanić Nebojša, et al.
Published: (2009-01-01)

Nedaplatin use in patients with hypersensitivity reaction episodes to carboplatin
by: Kenro Chikazawa, et al.
Published: (2020-07-01)

Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
by: Maurie Markman
Published: (2009-02-01)

Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies
by: Yu-Hsiao Tai, et al.
Published: (2017-11-01)

Carboplatin +/- topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma.
by: Jasmine H Francis, et al.
Published: (2013-01-01)

Carboplatin-Induced Bilateral Papilledema: A Case Report
by: N. Fischer, et al.
Published: (2009-04-01)

THE DIFFERENCES OF APOPTOSIS EFFECTS BETWEEN COMBINATION OF MELOXICAM WITH GEMCITABINE-CARBOPLATIN CHEMOTHERAPY COMPARED TO GEMCITABINE-CARBOPLATIN CHEMOTHERAPY ALONE IN UROTHELIAL CARCINOMA CULTURE CELLS
by: Ananta Cahyo Nugroho, et al.
Published: (2019-01-01)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
by: S B Dessai, et al.
Published: (2016-01-01)